{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:13:29Z","timestamp":1781561609078,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1136\/ard.2008.087957","type":"journal-article","created":{"date-parts":[[2008,4,18]],"date-time":"2008-04-18T00:55:55Z","timestamp":1208480155000},"page":"1528-1534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"title":["Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease"],"prefix":"10.1016","volume":"68","author":[{"given":"G","family":"Hatemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Silman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Houman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P P","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"St\u00fcbiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Yurdakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.087957_bib1","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Behcet\u2019s disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.087957_bib2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.62.4.316","article-title":"Number needed to treat (NNT): implication in rheumatology clinical practice","volume":"62","author":"Osiri","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.087957_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Behcet\u2019s syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.087957_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780400425","article-title":"Azathioprine in Behcet\u2019s syndrome: effects on long-term prognosis","volume":"40","author":"Hamuryudan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.087957_bib5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/BF02235590","article-title":"Long-term clinical course and prognostic factors in intestinal Behcet\u2019s disease","volume":"43","author":"Choi","year":"2000","journal-title":"Dis Colon Rectum"},{"issue":"(Suppl","key":"10.1136\/ard.2008.087957_bib6","first-page":"928","article-title":"Interferon \u03b1 combined with azathioprine for the uveitis of Behcet\u2019s disease: an open study","volume":"4","author":"Hamuryudan","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"10.1136\/ard.2008.087957_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet\u2019s syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1136\/ard.2008.087957_bib8","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Behcet\u2019s syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.2008.087957_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet\u2019s disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1136\/ard.2008.087957_bib10","first-page":"391","article-title":"Treatment of thrombophlebitis of Behcet\u2019s disease with low dose cyclosporin A","volume":"17","author":"Cantini","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib11","first-page":"321","article-title":"The efficacy of cyclosporin-A in the treatment of Behcet\u2019s disease","volume":"25","author":"Atmaca","year":"1994","journal-title":"Ophthalmic Surg"},{"key":"10.1136\/ard.2008.087957_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00161239","article-title":"Cyclosporine effects on optic nerve and retinal vasculitis in Behcet\u2019s disease","volume":"80","author":"Chavis","year":"1992","journal-title":"Doc Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/0-306-48382-3_114","article-title":"Efficacy of corticosteroids and cyclosporin in the treatment of retinal vasculitis in patients with Behcet\u2019s disease","volume":"528","author":"Ermakova","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2008.087957_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0021-5155(99)00025-8","article-title":"Ciclosporin microemulsion preconcentrate treatment of patients with Behcet\u2019s disease","volume":"43","author":"Fujino","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000310490","article-title":"Visual prognosis in patients with Behcet\u2019s disease receiving colchicine, systemic corticosteroid or cyclosporin","volume":"208","author":"Hayasaka","year":"1994","journal-title":"Ophthalmologica"},{"key":"10.1136\/ard.2008.087957_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1021227019915","article-title":"Long-term therapy with low dose cyclosporin A in ocular Behcet\u2019s disease","volume":"105","author":"Ozdal","year":"2002","journal-title":"Doc Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF02249016","article-title":"Cyclosporin in Behcet\u2019s disease: results in 16 patients after 24 months of therapy","volume":"13","author":"Pacor","year":"1994","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jop.1994.10.553","article-title":"Low dose cyclosporin-A therapy in Behcet\u2019s disease","volume":"10","author":"Sajjadi","year":"1994","journal-title":"J Ocul Pharmacol"},{"key":"10.1136\/ard.2008.087957_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin-A therapy in severe uveitis of Behcet\u2019s disease","volume":"76","author":"Sullu","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1136\/ard.2008.087957_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9394(14)72840-5","article-title":"Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet\u2019s disease","volume":"118","author":"Whitcup","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","article-title":"Effectiveness of cyclosporin therapy for Behcet\u2019s disease","volume":"28","author":"Nussenblatt","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.087957_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/bjo.71.5.387","article-title":"Short term cyclosporin A treatment of Behcet\u2019s disease","volume":"71","author":"Muftuoglu","year":"1987","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/art.1780290420","article-title":"Cyclosporin A is effective, but not safe, in the management of Behcet\u2019s disease","volume":"29","author":"Wechsler","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"(Suppl","key":"10.1136\/ard.2008.087957_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713689008999414","article-title":"Cyclosporin A treatment of Behcet\u2019s disease: a long-term study","volume":"9","author":"Diaz-Llopis","year":"1990","journal-title":"Curr Eye Res"},{"key":"10.1136\/ard.2008.087957_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/rheumatology\/26.4.285","article-title":"Cyclosporin A in the treatment of severe Behcet\u2019s uveitis","volume":"26","author":"Binder","year":"1987","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","article-title":"Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy","volume":"106","author":"Kotake","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2008.087957_bib27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","article-title":"CNS involvement occurs more frequently in patients with Behcet\u2019s disease under cyclosporin A (CSA) than under other medications - results of a retrospective analysis of 117 cases","volume":"25","author":"Kotter","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","article-title":"Central nervous system symptoms in a population of Behcet\u2019s disease patients with refractory uveitis treated with cyclosporine A","volume":"29","author":"Kato","year":"2001","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon \u03b1-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2008.087957_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon-\u03b12a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2008.087957_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon \u03b1-2a for the treatment of with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon \u03b1-2a in severe and refractory uveitis associated with Behcet\u2019s disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard.2008.087957_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib34","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-\u03b1 therapy in patients with Behcet uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/0-306-48382-3_103","article-title":"Interferon \u03b1-2a in the treatment of ocular Adamantiades-Behcet\u2019s disease","volume":"528","author":"Krause","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2008.087957_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Behcet\u2019s disease: an open study","volume":"62","author":"Calguneri","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.087957_bib37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0190-9622(94)70226-8","article-title":"Interferon therapy for Behcet\u2019s disease","volume":"31","author":"Alpsoy","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2008.087957_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000246374","article-title":"Interferon \u03b1-2a in the treatment of Behcet\u2019s disease","volume":"192","author":"Azizlerli","year":"1996","journal-title":"Dermatology"},{"key":"10.1136\/ard.2008.087957_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000018427","article-title":"Long-term effects of interferon alpha 2A treatment in Behcet\u2019s disease","volume":"201","author":"Boyvat","year":"2000","journal-title":"Dermatology"},{"key":"10.1136\/ard.2008.087957_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","article-title":"Efficacy and safety of systemic recombinant interferon-alpha in Behcet\u2019s disease","volume":"243","author":"Georgiou","year":"1998","journal-title":"J Intern Med"},{"key":"10.1136\/ard.2008.087957_bib41","first-page":"1938","article-title":"Interferon-alpha treatment of Behcet\u2019s disease","volume":"25","author":"O\u2019Duffy","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib42","first-page":"440","article-title":"Adamantiades-Behcet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a","volume":"44","author":"Zouboulis","year":"1993","journal-title":"Hautarzt"},{"key":"10.1136\/ard.2008.087957_bib43","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Behcet\u2019s disease - review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.087957_bib44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2008.087957_bib45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"34","key":"10.1136\/ard.2008.087957_bib46","first-page":"S14","article-title":"Infliximab in refractory uveitis due to Behcet\u2019s disease","volume":"22","author":"Wechsler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib47","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet\u2019s disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.087957_bib48","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib49","first-page":"50","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet\u2019s disease","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib50","first-page":"98","article-title":"Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/rheumatology\/33.1.48","article-title":"Pulmonary arterial aneurysms in Behcet\u2019s syndrome: a report of 24 cases","volume":"33","author":"Hamuryudan","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib52","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjmed.2004.05.027","article-title":"Pulmonary artery aneurysms in Behcet syndrome","volume":"117","author":"Hamuryudan","year":"2004","journal-title":"Am J Med"},{"key":"10.1136\/ard.2008.087957_bib53","first-page":"1355","article-title":"Value of \u201cbolus\u201d cyclophosphamide injections in Behcet\u2019s disease. Experience of cases","volume":"19","author":"Du","year":"1990","journal-title":"Presse Med"},{"key":"10.1136\/ard.2008.087957_bib54","first-page":"438","article-title":"Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet\u2019s disease. Preliminary results with the use of new criteria of evaluation","volume":"143","author":"Hamza","year":"1992","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1136\/ard.2008.087957_bib55","first-page":"508","article-title":"Treatment of Behcet\u2019s disease with cyclophosphamide","volume":"77","author":"Oniki","year":"1973","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1136\/ard.2008.087957_bib56","first-page":"148","article-title":"Long-term effects of cyclophosphamide and colchicine treatment in Behcet\u2019s disease","volume":"23","author":"Kazokoglu","year":"1991","journal-title":"Ann Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib57","first-page":"399","article-title":"A double blind study of colchicine in Behcet\u2019s disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"key":"10.1136\/ard.2008.087957_bib58","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Behcet\u2019s syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.087957_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0714.2004.00265.x","article-title":"Clinical and immunological effects of azithromycin in Behcet\u2019s disease","volume":"34","author":"Mumcu","year":"2005","journal-title":"J Oral Pathol Med"},{"key":"10.1136\/ard.2008.087957_bib60","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(77)92945-2","article-title":"Colchicine in Behcet\u2019s disease","volume":"2","author":"Mizushima","year":"1977","journal-title":"Lancet"},{"key":"10.1136\/ard.2008.087957_bib61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D30N02G93T","article-title":"Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study","volume":"11","author":"Al-Waiz","year":"2005","journal-title":"Dermatol Online J"},{"key":"10.1136\/ard.2008.087957_bib62","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2008.087957_bib63","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/ard.53.12.828","article-title":"Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet\u2019s disease: use of neurophysiological studies to detect thalidomide neuropathy","volume":"53","author":"Gardner-Medwin","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.087957_bib64","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/archderm.1982.01650200004003","article-title":"Thalidomide in the treatment of Behcet\u2019s syndrome","volume":"118","author":"Saylan","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2008.087957_bib65","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02054255","article-title":"Treatment of Behcet\u2019s disease with thalidomide","volume":"5","author":"Hamza","year":"1986","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib66","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.1780391216","article-title":"The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet\u2019s disease. A randomized clinical trial","volume":"39","author":"Calguneri","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.087957_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000246336","article-title":"Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet\u2019s disease","volume":"192","author":"Calguneri","year":"1996","journal-title":"Dermatology"},{"key":"10.1136\/ard.2008.087957_bib68","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3349\/ymj.1997.38.6.444","article-title":"Streptococcal infection in the pathogenesis of Beh\u00e7et's disease and clinical effects of minocycline on the disease symptoms","volume":"38","author":"Kaneko","year":"1997","journal-title":"Yonsei Med J"},{"key":"10.1136\/ard.2008.087957_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0714.2004.00265.x","article-title":"Clinical and immunological effects of azithromycin in Behcet\u2019s disease","volume":"34","author":"Mumcu","year":"2005","journal-title":"J Oral Pathol Med"},{"key":"10.1136\/ard.2008.087957_bib70","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.1780250621","article-title":"Treatment of Behcet\u2019s disease with levamisole","volume":"25","author":"Hamza","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.087957_bib71","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/rheumatology\/27.4.300","article-title":"Treatment with acyclovir does not affect orogenital ulcers in Behcet\u2019s syndrome: a randomized double-blind trial","volume":"27","author":"Davies","year":"1988","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib72","first-page":"493","article-title":"Inefficacy of azapropazone in the acute arthritis of Behcet\u2019s syndrome: a randomized, double blind, placebo controlled study","volume":"13","author":"Moral","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib73","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-4362.1991.tb05883.x","article-title":"Treatment of Behcet disease with indomethacin","volume":"30","author":"Simsek","year":"1991","journal-title":"Int J Dermatol"},{"key":"10.1136\/ard.2008.087957_bib74","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02032350","article-title":"Efficacy of oxaprozin in the treatment of articular symptoms of Behcet\u2019s disease","volume":"3","author":"Takeuchi","year":"1984","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib75","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","article-title":"A double-blind trial of depot corticosteroids in Behcet\u2019s syndrome","volume":"45","author":"Mat","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.087957_bib76","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/sj.eye.6700464","article-title":"Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet's disease","volume":"17","author":"Cashay","year":"2003","journal-title":"Eye"},{"key":"10.1136\/ard.2008.087957_bib77","first-page":"3343","article-title":"A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet\u2019s disease. Japanese FK 506 Study Group on Refractory Uveitis","volume":"23","author":"Mochizuki","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.2008.087957_bib78","first-page":"802","article-title":"A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behcet\u2019s disease and allied conditions","volume":"35","author":"Sakane","year":"1995","journal-title":"Ryumachi"},{"key":"10.1136\/ard.2008.087957_bib79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/0-306-48382-3_118","article-title":"High dose methotrexate for ocular lesions of Behcet\u2019s disease. Preliminary short-term results","volume":"528","author":"Davatchi","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2008.087957_bib80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00126839-200304010-00002","article-title":"Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet\u2019s disease: a randomised, double-blind, placebo-controlled study","volume":"4","author":"Matsuda","year":"2003","journal-title":"Drugs R D"},{"key":"10.1136\/ard.2008.087957_bib81","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","article-title":"Dapsone in Behcet\u2019s disease: a double-blind, placebo-controlled, cross-over study","volume":"29","author":"Sharquie","year":"2002","journal-title":"J Dermatol"},{"key":"10.1136\/ard.2008.087957_bib82","series-title":"Beh\u00e7et\u2019s syndrome","first-page":"227","article-title":"Failure of transfor factor in the treatment of Beh\u00e7et\u2019s syndrome: a double blind trial","author":"Denman","year":"1979"},{"key":"10.1136\/ard.2008.087957_bib83","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1346-8138.2006.00128.x","article-title":"Oral zinc sulfate in the treatment of Behcet\u2019s disease: a double blind cross-over study","volume":"33","author":"Sharquie","year":"2006","journal-title":"J Dermatol"},{"key":"10.1136\/ard.2008.087957_bib84","first-page":"264","article-title":"Behcet\u2019s syndrome: treatment with chlorambucil","volume":"82","author":"Elliott","year":"1984","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1136\/ard.2008.087957_bib85","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archopht.1976.03910030274004","article-title":"Treatment of Behcet disease with chlorambucil. A follow-up report","volume":"94","author":"Mamo","year":"1976","journal-title":"Arch Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib86","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1076\/ocii.9.4.219.3957","article-title":"Short-term chlorambucil for refractory uveitis in Behcet\u2019s disease","volume":"9","author":"Mudun","year":"2001","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard.2008.087957_bib87","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0161-6420(83)80014-1","article-title":"Chlorambucil in Behcet\u2019s disease. A reappraisal","volume":"90","author":"Tabbara","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2008.087957_bib88","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/bjo.74.6.353","article-title":"High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet\u2019s disease","volume":"74","author":"Tessler","year":"1990","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2008.087957_bib89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9343(84)90753-8","article-title":"Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet\u2019s disease","volume":"76","author":"O\u2019Duffy","year":"1984","journal-title":"Am J Med"},{"key":"10.1136\/ard.2008.087957_bib90","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/0-306-48382-3_117","article-title":"Low dose MTX for progressive neuro-Behcet\u2019s disease. A follow-up study for 4 years","volume":"528","author":"Kikuchi","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2008.087957_bib91","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-510X(98)00165-8","article-title":"Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet\u2019s disease","volume":"159","author":"Hirohata","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1136\/ard.2008.087957_bib92","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archderm.135.5.529","article-title":"The use of sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease: a randomized, placebo-controlled, double-blind study","volume":"135","author":"Alpsoy","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2008.087957_bib93","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/rheumatology\/30.5.395-a","article-title":"Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet\u2019s syndrome: a randomized, double blind trial","volume":"30","author":"Hamuryudan","year":"1991","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2008.087957_bib94","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-4362.1997.tb03133.x","article-title":"Topical cyclosporine-A for treatment of oral ulcers of Behcet\u2019s syndrome","volume":"36","author":"Ergun","year":"1997","journal-title":"Int J Dermatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724216162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724216162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.087957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:54:20Z","timestamp":1737438860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724216162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0003496724216162"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.087957","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.087957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Inc. Publishing Group Ltd and European League Against Rheumatism. All rights reserved. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}